Stephanie B. Seminara, MD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Stephanie B. Seminara, MD sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 4 currently recruiting 6 completed early-phase tilt top decile by trial count

Stephanie B. Seminara, MD: 11 sponsored US clinical trials, 4 recruiting.

Stephanie B. Seminara, MD sponsors 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypogonadotropic Hypogonadism, with 4 trials.

Top-decile sponsor footprint

Stephanie B. Seminara, MD ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCT07224490
RECRUITING Phase 2

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

NCT07224438
RECRUITING Phase 2

Kisspeptin Administration Subcutaneously to Patients With IHH

NCT05896293
RECRUITING

The Molecular Basis of Inherited Reproductive Disorders

NCT05971836
COMPLETED NA

Using Visual Arrays to Support Understanding of Genetic Risk

NCT06994832
COMPLETED Phase 1

Opioid Antagonism in Hypogonadotropic Hypogonadism

NCT04975334
TERMINATED Phase 1

Recall by Genotype: Neuropeptide Stimulation

NCT05901467
COMPLETED Phase 1

Dampening the Reproductive Axis With Continuous Kisspeptin

NCT05971849
COMPLETED Phase 1

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

NCT05633966
COMPLETED Phase 1

Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank

NCT04975347
COMPLETED Phase 2

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

NCT04648969

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3

Therapeutic Areas

Hypogonadotropic Hypogonadism 4
Reproductive Disorder 2
Reproductive Disorders 1
Low Testosterone 1
Delayed Puberty 1
Kallmann Syndrome 1
Neurodegeneration 1
Hypothalamic Amenorrhea 1
SARS-CoV-2 1

What is open in the Stephanie B. Seminara, MD pipeline

4 recruiting of 11 indexed (36% open); 6 completed (55%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Hypogonadotropic Hypogonadism (4 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Stephanie B. Seminara, MD: open-pipeline peers nationwide

Peers matched on 11 registered trials and 36% open enrollment, not the therapeutic-area sidebar.

Stephanie B. Seminara, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Stephanie B. Seminara, MDAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeCooperVision International Limited (CVIL)BioNTech SEMichael J. Fox Foundation for Parkinson's ResearchTrustees of Dartmouth College
Stephanie B. Seminara, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Stephanie B. Seminara, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 36% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stephanie B. Seminara, MD page

11 registered trials is a research-attention snapshot, not an endorsement of Stephanie B. Seminara, MD or any single study.

  • 4 of Stephanie B. Seminara, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hypogonadotropic Hypogonadism is the condition Stephanie B. Seminara, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypogonadotropic Hypogonadism trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Stephanie B. Seminara, MD pipeline card: 11 registered trials from official public datasets.Report a data error.